Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis Holds Lead In Oral MS Space With Fingolimod Filing

Executive Summary

Novartis has gained the lead in the race to market for the first oral therapy for multiple sclerosis with the NDA submission for fingolimod, a feat made possible by FDA's refusal to file the earlier NDA for Merck Serono's oral MS candidate cladribine

You may also be interested in...

If Novartis's Gilenia Clears Safety Hurdle, Other Oral MS Drugs May Have An Easier Path

While fingolimod has a broadly similar safety profile to Merck Serono's cladribine and Teva's laquinimod, additional cardiac, pulmonary and ophthalmic adverse events may give Novartis's first mover a higher barrier to clear.

Novartis Talking About Fingolimod Safety With FDA; Will Talk To Advisory Panel In June

Structure of the REMS for oral multiple sclerosis drug Gilenia likely to be discussed at committee meeting close to review deadline.

Despite Ocrelizumab Infection Risk, Roche Sees Multiple Sclerosis Opportunity

Anti-CD20 molecule's future in RA was dashed by high infection risk, but Roche says the safety profile of ocrelizumab could be better in MS patients.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts